Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 7/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8670836 | 0.90 | AHR (0.59) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL17080910 | 0.87 | AHR (0.53) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL260278 | 0.86 | AHR (0.56) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL4551283 | 0.84 | SMYD3 (0.50) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL7349900 | 0.83 | AHR (0.53) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL4404868 | 0.83 | AHR (0.57) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL15941764 | 0.83 | SMYD3 (0.55) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL5728887 | 0.81 | AHR (0.54) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL689189 | 0.81 | AHR (0.50) | AHRMAOBSMYD3HTR1ADRD2 | |
| SCHEMBL20821103 | 0.80 | AHR (0.49) | AHRMAOBSMYD3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101987848-B | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing the same | SERVIER LAB | 2014-06-18 | — | — | CN | disclosed |
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2281822-B1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-16 | — | — | EP | disclosed |
| US-8133889-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-13 | — | — | US | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
| CN-101987848-A | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB | 2011-03-23 | — | — | CN | disclosed |
| WO-2011015728-A1 | NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | WO | disclosed |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | AHR 267/4885MAOB 1216/4885SMYD3 2174/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | AHR 267/4885MAOB 1216/4885SMYD3 2174/4885 |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | AHR 267/4885MAOB 1216/4885SMYD3 2174/4885 |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | AHR 603/4885MAOB 867/4885SMYD3 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.